地舒单抗多少钱？

With changes in diet and lifestyle and the extension of life expectancy, osteoporosis has become one of the most common diseases threatening human health in modern society. Osteoporosis refers to a systemic skeletal disease characterized by reduced bone mass and degradation and destruction of bone microstructure due to physiological and pathological reasons, resulting in reduced bone strength and increased risk of fractures. Currently, commonly used drugs in clinical practice include bone mineralization-promoting agents, bone resorption inhibitors (), bone formation stimulators and some proprietary Chinese medicines.

Denosumab (Xgeva, Denosumab) is a new RANKL inhibitor developed by Amgen. It is a fully humanized monoclonal IgG2 antibody to RANKL and has high affinity and specificity for the soluble, transmembrane form of human RANKL. In patients with giant cell tumors of bone, inhibition of RANKL secreted by tumor stromal components with denosumab significantly reduced or eliminated osteoclast-like tumor-associated giant cells. As a result, osteolysis is reduced, giant cell tumor progression is slowed, and the proliferative matrix is ​​replaced by dense nonproliferative, differentiated woven new bone, thereby improving clinical outcomes.

Usage and dosage: Give 120 mg by subcutaneous injection into the upper arm, upper thigh, or abdomen, once every 4 weeks. 120 mg/1.7 mL (70 mg/mL) single use vial.

On June 13, 2013, Denosumab was approved to treat adults and adolescents with giant cell tumor of bone (GCTB), a rare and usually noncancerous tumor.

What is the price of Xgeva?

The price of denosumab 120mg produced by Amgen in the United States is about $3,000.

It is a new drug from abroad and has not yet been launched in China. If you want to buy denosumab, you can buy it through the regular overseas medical service company Medical Companion Travel.